|
Indications And Usage: The Components Of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/tetracycline Hydrochloride Capsules (Bismuth Subsalicylate, Metronidazole, And Tetracycline Hydrochloride), In Combination With An H 2 Antagonist, Are Indicated For The Eradication Of H. Pylori For Treatment Of Patients With H. Pylori Infection And Duodenal Ulcer Disease (Active Or A History Of Duodenal Ulcer). The Eradication Of H. Pylori Has Been Demonstrated To Reduce The Risk Of Duodenal Ulcer Recurrence In Patients With Active Duodenal Ulcer Disease (See Clinical Studies And Dosage And Administration ). To Reduce The Development Of Drug-Resistant Bacteria And Maintain The Effectiveness Of Bismuth Subsalicylate Chewable Tablets/metronidazole Tablets/tetracycline Hydrochloride Capsules And Other Antibacterial Drugs, Bismuth Subsalicylate Chewable Tablets/metronidazole Tablets/tetracycline Hydrochloride Capsules Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antibacterial Therapy. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy.
|